



News Release

Suven's Income increased by 3% and PAT lower by 25% for the year ended March 2015

HYDERABAD, INDIA (26 May 2015) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, and Contract Research and Manufacturing Services (CRAMS) today announced its audited financial results for the year ended 31st Mar 2015. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 26th May 2015 at Hyderabad.

Financial Highlights for the year ended Mar' 2015:

Growth in revenue Rs 5294 Mn vs. Rs 5133 Mn - Up by 3%
Growth in PAT Rs 1088 Mn vs. Rs 1442 Mn - Down by 25%
Growth in EBIDTA Rs 1680 Mn vs. Rs 2221 Mn - Down by 24%

Financial Highlights for the 4th Quarter ended Mar' 2015:

Growth in revenue Rs 1145 Mn vs. Rs 1320 Mn - Down by 13%
Growth in PAT Rs 169 Mn vs. Rs 324 Mn - Down by 48%
Growth in EBIDTA Rs 265 Mn vs. Rs 486 Mn - Down by 45%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 560 Mn (10.57% on revenue) for the year ended March 31, 2015

The Board has proposed a Dividend of Re. 0.60 per share (60% of face value Rs. 1.00 each) for the financial year 2014-15, subject to approval of the shareholders in the ensuing Annual General Meeting.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

